Saniona targets late — October FDA IND filing for SAN2465 ahead of Phase 1 trial in healthy volunteers

Saniona released new preclinical evidence supporting SAN2465 as a potential rapid-acting oral antidepressant; results were presented in this announcement. The studies showed improved measures of brain synaptic function, reinforcing earlier animal findings of rapid, sustained antidepressant-like effects. Saniona is preparing a US IND filing for SAN2465, expected by end-October 2026, ahead of a Phase 1 trial in healthy volunteers. The planned study will assess safety, tolerability, pharmacokinetics, and biomarker readouts intended to guide later-stage development and dosing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein. (C)